Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors

Emons, Günter; Kaufmann, Manfred; Gorchev, Grigor; Tsekova, Valentina; Gründker, Carsten; Günthert, Andreas R; Hanker, Lars C; Velikova, Maya; Sindermann, Herbert; Engel, Jürgen; Schally, Andrew V (2010). Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. Gynecologic oncology, 119(3), pp. 457-61. Orlando, Fla.: Elsevier 10.1016/j.ygyno.2010.08.003

Full text not available from this repository. (Request a copy)

Receptors for luteinizing hormone-releasing hormone (LHRH) can be utilized for targeted chemotherapy of cytotoxic LHRH analogs. The compound AEZS-108 (previously AN-152) consists of [D-Lys?]LHRH linked to doxorubicin. The objectives of this first study in humans with AESZ-108 were to determine the maximum tolerated dose and to characterize the dose-limiting toxicity, pharmacokinetics, preliminary efficacy, and hormonal effects.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Gynaecology

UniBE Contributor:

Günthert, Andreas Reinhold

ISSN:

0090-8258

Publisher:

Elsevier

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:13

Last Modified:

17 Mar 2015 19:16

Publisher DOI:

10.1016/j.ygyno.2010.08.003

PubMed ID:

20828803

Web of Science ID:

000284556800011

URI:

https://boris.unibe.ch/id/eprint/3143 (FactScience: 206614)

Actions (login required)

Edit item Edit item
Provide Feedback